Santen Pharmaceutical Valuation
| SNPHF Stock | USD 10.53 0.62 5.56% |
At this time, the company appears to be overvalued. Santen Pharmaceutical has a current Real Value of $9.05 per share. The regular price of the company is $10.53. Our model measures the value of Santen Pharmaceutical from inspecting the company fundamentals such as Shares Outstanding of 388.22 M, return on equity of -0.0264, and insignificant Operating Margin as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Santen Pharmaceutical's price fluctuation is somewhat reliable at this time. Calculation of the real value of Santen Pharmaceutical is based on 3 months time horizon. Increasing Santen Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Santen pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Santen Pharmaceutical Co. Since Santen Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Santen Pink Sheet. However, Santen Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.53 | Real 9.05 | Hype 10.53 |
The real value of Santen Pink Sheet, also known as its intrinsic value, is the underlying worth of Santen Pharmaceutical Company, which is reflected in its stock price. It is based on Santen Pharmaceutical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Santen Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Santen Pharmaceutical Co helps investors to forecast how Santen pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Santen Pharmaceutical more accurately as focusing exclusively on Santen Pharmaceutical's fundamentals will not take into account other important factors: Santen Pharmaceutical Total Value Analysis
Santen Pharmaceutical Co is at this time forecasted to have takeover price of 2.6 B with market capitalization of 2.95 B, debt of 32.93 B, and cash on hands of 69.53 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Santen Pharmaceutical fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.6 B | 2.95 B | 32.93 B | 69.53 B |
Santen Pharmaceutical Investor Information
About 54.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.39. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Santen Pharmaceutical last dividend was issued on the 30th of March 2023. The entity had 5:1 split on the 27th of March 2015. Santen Pharmaceutical Co is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Santen Pharmaceutical Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Santen implies not a very effective usage of assets in December.Santen Pharmaceutical Ownership Allocation
Santen Pharmaceutical shows a total of 388.22 Million outstanding shares. Over half of Santen Pharmaceutical's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Santen Pharmaceutical Profitability Analysis
The company reported the revenue of 266.26 B. Net Income was 27.22 B with profit before overhead, payroll, taxes, and interest of 156.59 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Santen Pharmaceutical's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Santen Pharmaceutical and how it compares across the competition.
About Santen Pharmaceutical Valuation
The pink sheet valuation mechanism determines Santen Pharmaceutical's current worth on a weekly basis. Our valuation model uses a comparative analysis of Santen Pharmaceutical. We calculate exposure to Santen Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Santen Pharmaceutical's related companies.Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 4315 people.
8 Steps to conduct Santen Pharmaceutical's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Santen Pharmaceutical's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Santen Pharmaceutical's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Santen Pharmaceutical's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Santen Pharmaceutical's revenue streams: Identify Santen Pharmaceutical's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Santen Pharmaceutical's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Santen Pharmaceutical's growth potential: Evaluate Santen Pharmaceutical's management, business model, and growth potential.
- Determine Santen Pharmaceutical's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Santen Pharmaceutical's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Santen Pharmaceutical Growth Indicators
Investing in growth stocks can be very risky. If the company such as Santen Pharmaceutical does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 400.4 M | |
| Quarterly Earnings Growth Y O Y | 0.232 | |
| Forward Price Earnings | 12.9534 | |
| Retained Earnings | 290.5 B |
Complementary Tools for Santen Pink Sheet analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |